Abstract
Symptom monitoring using electronic patient-reported outcomes (ePROs) has demonstrated benefits for patients with cancer, yet the systematic effects for lung cancer remains unknown. This study performed a literature search in Medline, Embase, Cochrane library, CINAHL and APA PsyInfo before April 23rd, 2025, and identified 5755 papers. 18 (0.31%) papers from 11 studies conducting symptom monitoring on ePROs and sending alerts of severe symptoms were included. The meta-analysis showed significant improvement in health-related quality of life (SMD = 2.44, P < 0.001) among patients with lung cancer, with an intervention duration of less than 6 months, 6 months and more than 6 months. When excluding studies that sent alerts to patients themselves, overall survival for lung cancer patients was significantly prolonged (HR = 0.54, 95% CI [0.22, 1.31], P = 0.031). Symptom burden, physical functioning, and healthcare service utilization was also advantaged, but implementation process and cost-effectiveness data was insufficient (Trial registration: CRD420251000397).